共 14 条
[1]
A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients
[J].
TUMOR BIOLOGY,
2014, 35 (02)
:987-994
Zhong, Runbo
;
Han, Baohui
;
Zhong, Hua
.
[2]
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
[J].
LANCET ONCOLOGY,
2014, 15 (01)
:59-68
Butts, Charles
;
Socinski, Mark A.
;
Mitchell, Paul L.
;
Thatcher, Nick
;
Havel, Libor
;
Krzakowski, Maciej
;
Nawrocki, Sergiusz
;
Ciuleanu, Tudor-Eliade
;
Bosquee, Lionel
;
Manuel Trigo, Jose
;
Spira, Alexander
;
Tremblay, Lise
;
Nyman, Jan
;
Ramlau, Rodryg
;
Wickart-Johansson, Gun
;
Ellis, Peter
;
Gladkov, Oleg
;
Pereira, Jose Rodrigues
;
Eberhardt, Wilfried Ernst Erich
;
Helwig, Christoph
;
Schroeder, Andreas
;
Shepherd, Frances A.
.
[3]
Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089).[J].Achim Rittmeyer;Vera Gorbunova;Anders Vikstr?m;Arnaud Scherpereel;Joo-Hang Kim;Myung-Ju Ahn;Antonio Chella;Christos Chouaid;Alicyn K. Campbell;Fabrice Barlesi.Journal of Thoracic Oncology.2013, 11
[4]
A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.[J].S.S. Ramalingam;A. Kotsakis;A.A. Tarhini;D.E. Heron;R. Smith;D. Friedland;D.P. Petro;L.E. Raez;J.R. Brahmer;J.S. Greenberger;S. Dacic;P. Hershberger;R.J. Landreneau;J.D. Luketich;C.P. Belani;A. Argiris.Lung Cancer.2013,
[5]
Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients
[J].
CANCER IMMUNOLOGY IMMUNOTHERAPY,
2013, 62 (01)
:65-73
Yang, Lili
;
Ren, Baozhu
;
Li, Hui
;
Yu, Jinpu
;
Cao, Shui
;
Hao, Xishan
;
Ren, Xiubao
.
[6]
Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study
[J].
CANCER IMMUNOLOGY IMMUNOTHERAPY,
2012, 61 (11)
:2125-2133
Li, Runmei
;
Wang, Changli
;
Liu, Liang
;
Du, Chunjuan
;
Cao, Shui
;
Yu, Jinpu
;
Wang, Shizhen Emily
;
Hao, Xishan
;
Ren, Xiubao
;
Li, Hui
.
[7]
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
[J].
LANCET ONCOLOGY,
2012, 13 (01)
:33-42
Pirker, Robert
;
Pereira, Jose R.
;
von Pawel, Joachim
;
Krzakowski, Maciej
;
Ramlau, Rodryg
;
Park, Keunchil
;
de Marinis, Filippo
;
Eberhardt, Wilfried E. E.
;
Paz-Ares, Luis
;
Stoerkel, Stephan
;
Schumacher, Karl-Maria
;
von Heydebreck, Anja
;
Celik, Ilhan
;
O'Byrne, Kenneth J.
.
[8]
Impact of dendritic cell vaccines pulsed with Wilms’ tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.[J].Hidenori Takahashi;Masato Okamoto;Shigetaka Shimodaira;Shun-ichi Tsujitani;Masaki Nagaya;Takefumi Ishidao;Junji Kishimoto;Yoshikazu Yonemitsu.European Journal of Cancer.2012,
[9]
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized; Double-Blind; Multicenter Phase II Study.[J].Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski;Fabrice Barlesi;Raju Chacko;Martin Sebastian;Joel Neal;Haolan Lu;Jean-Marie Cuillerot;Martin Reck.Journal of Clinical Oncology.2012, 17
[10]
Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC Results from the Phase IV MO19390 (SAiL) Study
[J].
JOURNAL OF THORACIC ONCOLOGY,
2011, 6 (06)
:1092-1097
Tsai, Chun-Ming
;
Au, Joseph Siu-kie
;
Chang, Gee-Chen
;
Cheng, Ashley Chi-kin
;
Zhou, Caicun
;
Wu, Yi-long
.